NeXeption, LLC has secured $21.5 million in Series A financing to form Alexar Therapeutics, Inc., focused on developing a portfolio of Liver X receptor (LXR) agonists for both systemic and local use. LXR agonists regulate multiple genetic pathways and have potent anti-inflammatory activity. The financing, led by New Science Ventures and Third Point Ventures with participation from Palo Alto Investors, will fund the initial development of Alexar’s lead compound, A-110, a topical LXR agonist for t...